Skip to main content
Top

15-04-2024 | Hepatitis C | Original Article

Hepatitis C virus core antigen: A diagnostic and treatment monitoring marker of hepatitis C virus in Indian population

Authors: Jaya Garg, Prashant Verma, Mridu Singh, Anupam Das, Anurag Pathak, Jyotsna Agarwal

Published in: Indian Journal of Gastroenterology

Login to get access

Abstract

Background

The diagnosis and treatment monitoring of hepatitis C is quite challenging. The screening test, i.e. antibody assay, is unable to detect acute cases, while the gold standard hepatitis C virus (HCV) reverse transcriptase polymerase chain reaction (RTPCR) assay is not feasible in resource-limited countries such as India due to high cost and infrastructure requirement. European Association for the Study of the Liver and World Health Organization have approved a new marker, i.e. HCV core antigen (HCVcAg) assay, as an alternative to molecular assay. In this study, we have evaluated HCVcAg assay for diagnosis and treatment monitoring follow-up in Indian population infected with hepatitis C.

Methods

Blood specimen of 90 clinically suspected cases of acute hepatitis C were tested simultaneously for anti-HCV antibody assay via ELISA (enzyme-linked immunoassay), HCVcAg assay by chemiluminescence immune assay (CLIA) and HCV RTPCR VL (viral load) assay. Thirty-four HCV RTPCR positive patients were further enrolled in treatment monitoring group whose blood samples were tested at the beginning of treatment, two weeks, four weeks and 12 weeks via HCV core Ag assay and HCV RTPCR Viral Load assay.

Results

Considering HCV RTPCR as gold standard, diagnostic performance of HCV core Ag assay and anti-HCV antibody assay was evaluated. The sensitivity and specificity of HCV core Ag assay were higher than that of anti-HCV Antibody assay, i.e. 88.3% and 100% vs. 23.3% and 83.3%, respectively. The overall diagnostic accuracy of HCV core Ag assay was 92.20%. Among treatment follow-up group, HCV core Ag levels correlated well with HCV viral load levels, at the beginning of treatment (baseline) till 12 weeks showing highly significant Spearman rank correlation coefficient of > 0.9 with HCV viral load levels.

Conclusions

HCV core Ag assay is a cost-effective, practically feasible substitute of HCV RTPCR viral load assay for diagnosis as well as long duration treatment monitoring of hepatitis C infection in resource-limited settings.

Graphical Abstract

Literature
1.
go back to reference World Health Organization. Global health sector strategy on viral hepatitis 2016–2021, towards ending viral hepatitis. Geneva: WHO; 2016. World Health Organization. Global health sector strategy on viral hepatitis 2016–2021, towards ending viral hepatitis. Geneva: WHO; 2016.
2.
go back to reference World Health Organization. Guidelines on hepatitis B and C testing. Geneva. Switzerland: World Health Organization; 2017. p. 2017. World Health Organization. Guidelines on hepatitis B and C testing. Geneva. Switzerland: World Health Organization; 2017. p. 2017.
3.
4.
go back to reference Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–74. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–74.
8.
go back to reference Arboledas JCA, Guerrero IP, Rodríguez MJB, et al. Hepatitis C virus core antigen in the management of patients treated with new direct-acting antivirals. Diagn Microbiol Infect Dis. 2017;89:29–34.CrossRefPubMed Arboledas JCA, Guerrero IP, Rodríguez MJB, et al. Hepatitis C virus core antigen in the management of patients treated with new direct-acting antivirals. Diagn Microbiol Infect Dis. 2017;89:29–34.CrossRefPubMed
9.
go back to reference Galli C, Julicher P, Plebani M. HCV core antigen comes of age: a new opportunity for the diagnosis of hepatitis C virus infection. Clin Chem Lab Med. 2018;56:880–8.CrossRefPubMed Galli C, Julicher P, Plebani M. HCV core antigen comes of age: a new opportunity for the diagnosis of hepatitis C virus infection. Clin Chem Lab Med. 2018;56:880–8.CrossRefPubMed
10.
go back to reference Benito R, Arribas J, Algarate S, Cebollada R, Gude MJ. Hepatitis C virus core antigen for screening organ donors and recipients. Diagn Microbiol Infect Dis. 2018;91:126–9.CrossRefPubMed Benito R, Arribas J, Algarate S, Cebollada R, Gude MJ. Hepatitis C virus core antigen for screening organ donors and recipients. Diagn Microbiol Infect Dis. 2018;91:126–9.CrossRefPubMed
11.
go back to reference Wang Y, Jie W, Ling J, Yuanshuai H. HCV core antigen plays an important role in the fight against HCV as an alternative to HCV-RNA detection. J Clin Lab Anal. 2021;35:e23755. Wang Y, Jie W, Ling J, Yuanshuai H. HCV core antigen plays an important role in the fight against HCV as an alternative to HCV-RNA detection. J Clin Lab Anal. 2021;35:e23755.
13.
go back to reference National guidelines for Diagnosis and Management of Viral Hepatitis. Ministry of Health and family welfare, Government of India. National Viral Hepatitis Control Program (NVHCP) National Health Portal Of India. 2018. Accessed 3/4/2023 National guidelines for Diagnosis and Management of Viral Hepatitis. Ministry of Health and family welfare, Government of India. National Viral Hepatitis Control Program (NVHCP) National Health Portal Of India. 2018. Accessed  3/4/2023
14.
go back to reference Alonso R, Pérez-García F, López-Roa P, Alcalá L, Rodeño P, Bouza E. HCV core-antigen assay as an alternative to HCV RNA quantification: a correlation study for the assessment of HCV viremia. Enferm Infecc Microbiol Clin (Engl Ed). 2018;36:175–8. Alonso R, Pérez-García F, López-Roa P, Alcalá L, Rodeño P, Bouza E.  HCV core-antigen assay as an alternative to HCV RNA quantification: a correlation study for the assessment of HCV viremia. Enferm Infecc Microbiol Clin (Engl Ed). 2018;36:175–8.
15.
go back to reference Rebucci C, Cerino A, Cividini A, Timo L, Furione M, Mondelli MU. Monitoring response to antiviral therapy for patients with chronic hepatitis C virus infection by a core-antigen assay. J Clin Microbiol. 2003;41:3881–4. Rebucci C, Cerino A, Cividini A, Timo L, Furione M, Mondelli MU. Monitoring response to antiviral therapy for patients with chronic hepatitis C virus infection by a core-antigen assay. J Clin Microbiol. 2003;41:3881–4.
16.
go back to reference Ponnuvel S, Fletcher GJ, Anantharam R, Varughese S, David VG, Abraham P. Clinical utility of hepatitis C virus core antigen (HCVcAg) assay to identify active HCV infection in hemodialysis and renal transplant patients. PLoS One. 2021;16:e0250263. Ponnuvel S, Fletcher GJ, Anantharam R, Varughese S, David VG, Abraham P. Clinical utility of hepatitis C virus core antigen (HCVcAg) assay to identify active HCV infection in hemodialysis and renal transplant patients. PLoS One. 2021;16:e0250263.
18.
go back to reference Harrison GL, Pryor J, Malani J, et al. Infection frequency of hepatitis C virus and IL28B haplotypes in Papua New Guinea, Fiji, and Kiribati. PLoS One. 2013;8:e66749. Harrison GL, Pryor J, Malani J, et al. Infection frequency of hepatitis C virus and IL28B haplotypes in Papua New Guinea, Fiji, and Kiribati. PLoS One. 2013;8:e66749.
19.
go back to reference Mateos P. Names, ethnicity and populations; tracing identity in space. Heidelberg: Springer; 2014. Mateos P. Names, ethnicity and populations; tracing identity in space. Heidelberg: Springer; 2014.
20.
go back to reference Mateos P. A review of name-based ethnicity classification methods and their potential in population studies. Popul Space Place. 2007;13:243–63.CrossRef Mateos P. A review of name-based ethnicity classification methods and their potential in population studies. Popul Space Place. 2007;13:243–63.CrossRef
21.
go back to reference Kumbhar N, Ramachandran K, Kumar G, Rao Pasupuleti SS, Sharma MK, Gupta E. Utility of hepatitis C virus core antigen testing for diagnosis and treatment monitoring in HCV infection: a study from India. Indian J Med Microbiol. 2021;39(4):462–6.CrossRefPubMed Kumbhar N, Ramachandran K, Kumar G, Rao Pasupuleti SS, Sharma MK, Gupta E. Utility of hepatitis C virus core antigen testing for diagnosis and treatment monitoring in HCV infection: a study from India. Indian J Med Microbiol. 2021;39(4):462–6.CrossRefPubMed
22.
go back to reference Kannan A, Biswas L, Kumar A, et al. Improving diagnosis of hepatitis C virus infection using hepatitis C core antigen testing in a resource-poor setting. Rev Soc Bras Med Trop. 2021;10:54. Kannan A, Biswas L, Kumar A, et al. Improving diagnosis of hepatitis C virus infection using hepatitis C core antigen testing in a resource-poor setting. Rev Soc Bras Med Trop. 2021;10:54.
23.
go back to reference Reddy AK, Dakshinamurty KV, Lakshmi V. Utility of HCV core antigen ELISA in the screening for hepatitis C virus infection in patients on hemodialysis. Indian J Med Microbiol. 2006;24:55–7.CrossRefPubMed Reddy AK, Dakshinamurty KV, Lakshmi V. Utility of HCV core antigen ELISA in the screening for hepatitis C virus infection in patients on hemodialysis. Indian J Med Microbiol. 2006;24:55–7.CrossRefPubMed
24.
go back to reference Medhi S, Potukuchi SK, Polipalli SK, et al. Diagnostic utility of hepatitis C virus core antigen in hemodialysis patients. Clin Biochem. 2008;41:447–52.CrossRefPubMed Medhi S, Potukuchi SK, Polipalli SK, et al. Diagnostic utility of hepatitis C virus core antigen in hemodialysis patients. Clin Biochem. 2008;41:447–52.CrossRefPubMed
25.
go back to reference Patel J, Sharma P. Design of a novel rapid immunoassay for simultaneous detection of hepatitis C virus core antigen and antibodies. Adv Virol. 2020;165:627–41. Patel J, Sharma P. Design of a novel rapid immunoassay for simultaneous detection of hepatitis C virus core antigen and antibodies. Adv Virol. 2020;165:627–41.
26.
go back to reference Shah H, Bilodeau M, Burak KW, et al. The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. CMAJ. 2018;190:E677–87.CrossRefPubMedPubMedCentral Shah H, Bilodeau M, Burak KW, et al. The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. CMAJ. 2018;190:E677–87.CrossRefPubMedPubMedCentral
27.
28.
go back to reference Bertisch B, Brezzi M, Negro F, et al. Swiss Hepatitis C Cohort Study. 2020. Very low hepatitis C viral loads in treatment-naive persons: do they compromise hepatitis C virus antigen testing? Clin Infect Dis 70:653–9. https://doi.org/10.1093/cid/ciz270 Bertisch B, Brezzi M, Negro F, et al. Swiss Hepatitis C Cohort Study. 2020. Very low hepatitis C viral loads in treatment-naive persons: do they compromise hepatitis C virus antigen testing? Clin Infect Dis 70:653–9. https://​doi.​org/​10.​1093/​cid/​ciz270
Metadata
Title
Hepatitis C virus core antigen: A diagnostic and treatment monitoring marker of hepatitis C virus in Indian population
Authors
Jaya Garg
Prashant Verma
Mridu Singh
Anupam Das
Anurag Pathak
Jyotsna Agarwal
Publication date
15-04-2024
Publisher
Springer India
Published in
Indian Journal of Gastroenterology
Print ISSN: 0254-8860
Electronic ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-024-01549-7
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.